Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT05320198 ↗

Phase 1/2 Recruiting 150 enrolled Disc Medicine, Inc

RandomizedSequentialOpen-labelTreatment

Summary

This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

Timeline

Start: 2022-06-06
Primary completion: 2027-05
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DISC-0974	Monoclonal antibody	—	Subcutaneous

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Summary

Timeline

Drugs

Indications